Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCURAY INCARAY · Entity 1170 | SVP, Chief Financial Officer | July 03, 2018 | July 07, 2018 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | EVP, CFO | September 09, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCURAY INC
Report date July 03, 2018 · Filed July 07, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 313,619 |
Reported balance
After 2018-07-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-07-03 · Sale · Disposed 14,641 · Balance 313,619 F1: Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States.
PROCEPT BioRobotics Corp
Report date September 09, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,355 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Sale · Disposed 373 · Balance 180,355 F1: The shares were sold by the reporting person pursuant to the Issuer's sell-to-cover process for tax withholding obligations in connection with the vesting of the Restricted Stock Units on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person pursuant to the Issuer's sell-to-cover process for tax withholding obligations in connection with the vesting of the Restricted Stock Units on September 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,888 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · derivative · entry 9 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,632 Underlying: Common Stock · 6,888 shares Expires 2028-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. F4 · derivative.exercise_date: The Stock Option was granted on October 23, 2018 and vested over a four year period. Read SEC document |
| December 08, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 6,888 | $40.02 | $275,639.85 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · nonDerivative · entry 6 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,523 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.0000 to $40.0350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 08, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 6,888 | $4.52 | $31,133.76 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · nonDerivative · entry 3 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,837 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · derivative · entry 8 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,520 Underlying: Common Stock · 3,837 shares Expires 2028-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. F4 · derivative.exercise_date: The Stock Option was granted on October 23, 2018 and vested over a four year period. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 3,837 | $40.00 | $153,480.00 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · nonDerivative · entry 5 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,411 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 3,837 | $4.52 | $17,343.24 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · nonDerivative · entry 2 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,360 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · derivative · entry 7 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,357 Underlying: Common Stock · 4,360 shares Expires 2028-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. F4 · derivative.exercise_date: The Stock Option was granted on October 23, 2018 and vested over a four year period. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 4,360 | $40.02 | $174,493.30 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · nonDerivative · entry 4 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,248 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.0000 to $40.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:58 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 4,360 | $4.52 | $19,707.20 |
DisclosureSEC source: 0001628280-23-041166 · wk-form4_1702076286.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2023. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 21:09 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 22,631 | $35.12 | $794,911.61 |
DisclosureSEC source: 0001628280-23-022292 · wk-form4_1686863336.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,523 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 19:54 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 706 | $31.84 | $22,479.04 |
DisclosureSEC source: 0001628280-23-008459 · wf-form4_167908284341886.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,154 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 31, 2022. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 22:24 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 22,046 | $34.36 | $757,546.86 |
DisclosureSEC source: 0001628280-23-007375 · wf-form4_167840063219981.xml · nonDerivative · entry 2 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,678 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.0000 to $34.9925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:24 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 818 | $35.16 | $28,757.44 |
DisclosureSEC source: 0001628280-23-007375 · wf-form4_167840063219981.xml · nonDerivative · entry 3 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,860 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.3600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:24 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 7,136 | $34.15 | $243,705.10 |
DisclosureSEC source: 0001628280-23-007375 · wf-form4_167840063219981.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.0000 to $34.7400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 47,732 | $0.00 Strike: $37.02 | $0.00 |
DisclosureSEC source: 0001628280-23-004325 · wf-form4_167701529342235.xml · derivative · entry 2 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,732 Underlying: Common Stock · 47,732 shares Expires 2033-02-15 F2 · derivative.exercise_date: 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2023 over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 26,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-004325 · wf-form4_167701529342235.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,860 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 1/4th of the RSUs shall vest on the anniversary of the vesting commencement date of March 5, 2023, and annually over a three year period thereafter, subject to continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:18 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 16,020 | $0.00 Strike: $34.99 | $0.00 |
DisclosureSEC source: 0001628280-22-008263 · wf-form4_164910706485228.xml · derivative · entry 2 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,020 Underlying: Common Stock · 16,020 shares Expires 2032-03-30 F2 · price: The Stock option was granted on March 31, 2022 and vests 1/48th on the anniversary of the vesting commencement date of March 15, 2022, and monthly over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. F2 · derivative.exercise_date: The Stock option was granted on March 31, 2022 and vests 1/48th on the anniversary of the vesting commencement date of March 15, 2022, and monthly over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:18 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 7,914 | $29.38 | $232,513.32 |
DisclosureSEC source: 0001628280-22-008263 · wf-form4_164910706485228.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,545 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on March 15, 2023, with one-quarter of the remaining RSUs vesting annually on each of the second, third, and fourth anniversary thereof, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 22:42 UTC | ACCURAY INC ARAY · Entity 1170 | SaleCommon Stock | 14,265 | $4.08 | $58,129.88 |
DisclosureSEC source: 0001138723-18-000021 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,995 F1 · shares: Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| July 03, 2018 Filed Jul 7, 2018 00:52 UTC Amendment | ACCURAY INC ARAY · Entity 1170 | SaleCommon Stock | 14,641 | $4.00 | $58,568.39 |
DisclosureSEC source: 0001138723-18-000032 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,619 F1 · shares: Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 22:10 UTC | ACCURAY INC ARAY · Entity 1170 | SaleCommon Stock | 2,997 | $4.65 | $13,936.05 |
DisclosureSEC source: 0001138723-18-000012 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,260 F1 · shares: Shares were automatically sold into the open market in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| December 01, 2017 Filed Dec 1, 2017 23:12 UTC | ACCURAY INC ARAY · Entity 1170 | SaleCommon Stock | 3,830 | $4.86 | $18,595.80 |
DisclosureSEC source: 0001138723-17-000066 · edgardoc.xml · nonDerivative · entry 2 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,257 F1 · shares: Shares were automatically sold into the open market in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 23:12 UTC | ACCURAY INC ARAY · Entity 1170 | SaleCommon Stock | 3,324 | $5.30 | $17,617.20 |
DisclosureSEC source: 0001138723-17-000066 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,087 F1 · shares: Shares were automatically sold into the open market in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 00:07 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 1,487 | $4.31 | $6,412.39 |
DisclosureSEC source: 0001138723-17-000050 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,411 F1 · shares: Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 22:19 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 6,185 | $4.00 | $24,740.00 |
DisclosureSEC source: 0001138723-17-000030 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,398 F1 · shares: Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 23:55 UTC | ACCURAY INC ARAY · Entity 1170 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 113,750 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001138723-17-000034 · edgardoc.xml · derivative · entry 2 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,750 Underlying: Common Stock · 113,750 shares Expires 2027-09-29 F2 · derivative.exercise_date: The options are exercisable as they vest. A total of 25% of the entire number of shares subject to this stock option becomes vested and fully exercisable on the first anniversary of the vesting commencement date and the remaining shares subject to this stock option vest and become exercisable in equal monthly installments, ratably over the following 36 months. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 23:55 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 45,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-17-000034 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,083 F1 · shares: The restricted stock units (RSUs) are released as they vest. A total of 25% of the shares subject to this grant become vested and are released on the first anniversary of the vesting commencement date and the remaining shares vest and are released at a rate of 25% a year on each anniversary of the vesting commencement date over the remaining three years. Read SEC document |
| June 30, 2017 Filed Jul 3, 2017 19:54 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 15,502 | $4.75 | $73,634.50 |
DisclosureSEC source: 0001138723-17-000024 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,583 F1 · shares: Represents shares of Common Stock that were withheld by the issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of RSUs. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:41 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 3,391 | $4.70 | $15,937.70 |
DisclosureSEC source: 0001138723-17-000002 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,085 Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 23:40 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 3,449 | $5.06 | $17,457.46 |
DisclosureSEC source: 0001138723-16-000144 · edgardoc.xml · nonDerivative · entry 2 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,476 F2 · price: A total of 3,449 shares were sold pursuant to a 10b5-1 Plan, at an average sale price of $5.061623 per share. The actual sale price for the shares was: 900 shares at $5.075 and 2,549 shares at $5.0569. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 23:40 UTC | ACCURAY INC ARAY · Entity 1170 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 95,500 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001138723-16-000144 · edgardoc.xml · derivative · entry 3 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,500 Underlying: Common Stock · 95,500 shares Expires 2026-11-30 F3 · derivative.exercise_date: The options are exercisable as they vest. A total of 25% of the entire number of shares subject to this stock option becomes vested and fully exercisable on the first anniversary of the vesting commencement date and the remaining shares subject to this stock option vest and become exercisable in equal monthly installments, ratably over the following 36 months. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 23:40 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 38,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-16-000144 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,925 F1 · shares: The restricted stock units (RSUs) are released as they vest. A total of 25% of the shares subject to this grant become vested and are released on the first anniversary of the vesting commencement date and the remaining shares vest and are released at a rate of 25% a year on each anniversary of the vesting commencement date over the remaining three years. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 22:12 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 1,393 | $4.85 | $6,756.05 |
DisclosureSEC source: 0001138723-16-000124 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,725 F1 · price: A total of 1,393 shares were sold at $4.85 per share to cover tax liability of RSU release pursuant to a 10b5-1 Plan. Read SEC document |
| October 03, 2016 Filed Oct 3, 2016 23:05 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 6,331 | $6.24 | $39,505.44 |
DisclosureSEC source: 0001138723-16-000116 · edgardoc.xml · nonDerivative · entry 1 Waters Kevin · CIK 0001653771 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,118 F1 · price: A total of 6,331 shares were sold at $6.24 per share to cover tax liability of RSU release pursuant to a 10b5-1 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.